Ontology highlight
ABSTRACT: Objective
Genetic polymorphisms might serve as useful prognostic markers for the timely diagnosis of RA. The purpose of this study was to identify genomic factors predictive of the occurrence of interstitial lung disease (ILD) in RA by performing a genome-wide association study of genetic variants, including single nucleotide polymorphisms (SNPs).Methods
The study population included 306 RA patients. All patients were treated with conventional DMARDs, including 6-16 mg MTX per week. Clinical data and venous blood samples were collected from all patients before administration of DMARDs. A total of 278 347 SNPs were analysed to determine their association with ILD occurrence.Results
Several SNPs were strongly associated with ILD occurrence (P < 10-5). rs6578890, which is located on chromosome 11 in the intronic region of the gene encoding tyrosine phosphatase receptor type F polypeptide-interacting protein-binding protein 2 (PPFIBP2), showed the strongest association with ILD occurrence (odds ratio 4.32, P = 10-7.93).Conclusion
PPFIBP2 could be a useful genetic marker for occurrence of interstitial pneumonia in RA patients and might help to identify the risk of ILD occurrence before RA treatment, thereby improving patient outcomes.
SUBMITTER: Hayashi S
PROVIDER: S-EPMC9651976 | biostudies-literature | 2022
REPOSITORIES: biostudies-literature
Hayashi Shinya S Matsubara Tsukasa T Fukuda Koji K Maeda Toshihisa T Funahashi Keiko K Hashimoto Marowa M Takashima Yoshinori Y Kikuchi Kenichi K Fujita Masahiro M Matsumoto Tomoyuki T Kuroda Ryosuke R
Rheumatology advances in practice 20221029 3
<h4>Objective</h4>Genetic polymorphisms might serve as useful prognostic markers for the timely diagnosis of RA. The purpose of this study was to identify genomic factors predictive of the occurrence of interstitial lung disease (ILD) in RA by performing a genome-wide association study of genetic variants, including single nucleotide polymorphisms (SNPs).<h4>Methods</h4>The study population included 306 RA patients. All patients were treated with conventional DMARDs, including 6-16 mg MTX per we ...[more]